Responses of CLL cells to purine analogs with cyclophosphamide ab 23.9 € als Taschenbuch: Drug-induced apoptosis of leukemic cells. Aus dem Bereich: Bücher, Wissenschaft, Biologie,
Responses of CLL cells to purine analogs with cyclophosphamide ab 23.9 EURO Drug-induced apoptosis of leukemic cells
Our findings demonstrate the need of ex vivo chronic lymphocytic leukemia cell (CLL) treatment before the application of drugs to select the most efficient manner of the patient s therapy. The obtained results confirm the link between the outcomes of the research done under ex vivo and in vivo conditions and underline the usefulness of ex vivo studies in the individual choice of CLL treatment. Our observations provide a base for further studies on the relationship between the in vivo clinical responses of patients and ex vivo pro-apoptotic activity, and the cytotoxicity of drugs against leukemic cells. Their validation by a study comprising a much larger group of patients is needed.
Chronic lymphocytic leukemia (CLL) is the most common hematological malignancy in western countries. It is characterized by the accumulation of monoclonal CD5+ B-lymphocytes in blood, bone marrow, and lymphoid organs, due to an imbalance between proliferation and cell death. It is a complex disease that remains misunderstood. This book, therefore describes globally this very common but extremely complex type of leukemia. Throughout this book the principal biological hallmarks of B-cells are compared with the principal features of CLL-leukemic B-cells. Additionally the current CLL epidemiology is indicated and the most common methods of diagnosis are discussed. Moreover, the principal prognostic factors of CLL are described, passing from a medical point of view to a biological description. The major characteristics conferring apoptotic avoidance of CLL cells and proliferation factors are detailed, such as the principal models for its in vitro and in vivo study. Finally, the leading conventional treatments and new therapeutic strategies against CLL are listed with their principal biological targets.
Coagulation disorders and abnormal platelet activation are frequent findings in hematological malignancies. A hypercoagulable state is induced by malignant cells interacting directly with haemostatic system and activating the coagulation cascade. This is descriptive, prospective analytical case- control study done in Radiation & Isotopes Center Khartoum (RICK) to determine the haemostatic abnormalities and vascular damage of hematological malignancies among the major Sudanese patients.Hemostasis studies shown that, there were decreased level of fibrinogenand antithrombin III, vWf and PAI-1 were significantly elevated in ALL and in AML patients. significantly low platelet counts in AML, CLL and increased in CML and CGL ( CML ph positive) in related to control group. D-dimers was positive in 79 % of patients.platelet aggregation in response to ADP, Collagen, and Epinephrine agonists was decreased in ALL, AML and MM, and in variable in CML and NHL, and increased in CLL and HL.Markers of coagulation and platelet defect was clearly observed in hematological malignancies patients, also indication of fibrinolysis and endothelial activation were confirmed
Flow cytometer became one of the most pivotal and definitive techniques in the diagnosis and classification of mature B cell neoplasm (MBCN). Since flow cytometer exploits the laser and photomultiplier technology for reliable high quality result with extremely high sensitivity and specificity, we used these important specifications in this project to study the properties of B cells in the adult patients whose have initial diagnosis of (MBCN). This book discussed the diversity of the flow cytometer parameters (such as the percentage of positive cells, the mean fluorescence intensity and the positive peak width) which showed a remarkable role in the diagnosis of MBCN and in differentiation between CLL and NHL. The worth of the idea of this diversity of the parameters exhibited in the minimization of the markers number following into the minimization of panel cost without affecting the result. Also, using of CD20 & CD19 with their flow cytometric parameters and without the other scoring markers showed a significant role in differentiation between CLL and NHL. These ideas are appropriate for the used in laboratories of limited resources.
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in western countries. One of the most important strategies in CLL chemotherapy is apoptosis induction in CLL cells. Over the last decades herbal medicines and their constituents attract the attentions for chemotherapy of CLL. Umbelliprenin is a sesquiterpene coumarin, that is synthesized by various Ferula species. Apoptosis induction and cytotoxicity toward cancerous cells by umbelliprenin, firstly showed in 2008. In my Ph.D thesis I studied the properties of apoptosis induction in CLL cell lines by umbelliprenin. For the first time I should that umbelliprenin could induce apoptosis in CLL cell lines time- and dose- dependently. umbelliprenin and other natural coumarins are hopeful compounds in the future of CLL chemotherapy.
Chronic lymphocytic leukemia is the most common leukemia affecting mainly elderly individuals and follows an extremely variable course, with survival ranging from months to decades. Several characteristics of CLL facilitate basic and translational research including the high population prevalence, the easily obtainable malignant cells through venous phlebotomy, the asymptomatic phase in most patients that allows for longitudinal evaluation, and the relatively long disease-specific survival. Consensus guidelines for treatment of patients with CLL have been proposed by the ESMO Clinical Practice Guidelines, and recently recommended that the current use of prognostic tools for patients with newly diagnosed CLL should include staging (Rai or Binet), lymphocyte doubling time (LDT), Beta-2 microglobulin (beta2M), CD38 and ZAP-70 markers, CLL-relevant fluorescence in situ hybridization (FISH) panel, and, if available, IgVH gene mutation status.
High Quality Content by WIKIPEDIA articles! High Quality Content by WIKIPEDIA articles! TGN1412 (also known as CD28-SuperMAB) is the working name of an immunomodulatory drug which was withdrawn from development. Originally intended for the treatment of B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis, it is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system's T cells. In its first human clinical trials in March 2006, it caused catastrophic systemic organ failure in the subjects, despite being administered at a supposed sub-clinical dose of 0.1 mg per kg, some 500 times lower than the dose found safe in animals. Six volunteers were hospitalized on 13 March 2006, at least four of these suffering from multiple organ dysfunction, and one trial volunteer is said to show signs of developing cancer.